Read, Watch or Listen

Eli Lilly posted third-quarter results that topped expectations and raised its outlook, sending shares up 5% premarket. Adjusted EPS reached $7.02 on revenue of $17.60 billion, beating estimates. The company now targets fiscal 2025 revenue of $63–$63.5 billion and full-year adjusted profit of $23–$23.70 per share. Demand for GLP-1 drugs powered the quarter: Mounjaro generated $6.52 billion, up 109% and above forecasts, while Zepbound brought in $3.57 billion, up 184% and slightly ahead of estimates. The strong showing comes as Lilly seeks to maintain its edge over Novo Nordisk in the booming obesity and diabetes market.

Prepared by Christopher Adams and reviewed by editorial team.